Launched by Mars Innovation and Evotec last year, Lab150 has now selected the first project to receive funding.
Lab150, a collaboration between commercialisation firm Mars Innovation and drug discovery company Evotec to drive research translation, yesterday identified its first project after launching in September 2017.
The size of the investment has not been confirmed.
The project relates to kallikrein-targeting compounds that have the potential to become a treatment for Netherton syndrome, a rare but severe inflammatory skin disease.
Symptoms include itchiness, a high absorption rate of substances such as lotions by the skin, an abnormal amount of dead…
